Synthesis of benzanilide derivatives as dual acting agents with α1-adrenoceptor antagonistic action and steroid 5-α reductase inhibitory activity
摘要:
Synthesis of benzanilide derivatives which have dual alpha(1)-adrenoceptor antagonistic action and steroid 5 alpha-reductase inhibitory activity and their structure-activity relationships is described, (C) 1998 Elsevier Science Ltd. All rights reserved.
Synthesis and Characterization of a Novel Liver-Targeted Prodrug of Cytosine-1-β-d-arabinofuranoside Monophosphate for the Treatment of Hepatocellular Carcinoma
摘要:
Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. These characteristics lead to poor efficacy, high toxicity, and a drug class associated with an unacceptable therapeutic index. Cyclic 1-aryl-1,3-propanyl phosphate prodrugs selectively release the monophosphate of a nucleoside (NMP) into CYP3A4-expressing cells, such as hepatocytes, while leaving the prodrug intact in plasma and extrahepatic tissues. This prodrug strategy was applied to the monophosphate of the well-known cytotoxic nucleoside cytosine-1-beta-D-arabinofuranoside (cytarabine, araC). Compound 19S (MB07133), in mice, achieves good liver targeting compared to araC, generating > 19-fold higher cytarabine triphosphate (araCTP) levels in the liver than levels of araC in the plasma and > 12-fold higher araCTP levels in the liver than in the bone marrow, representing a > 120-fold and > 28-fold improvement, respectively, over araC administration.
Lewis Base-Promoted Ring-Opening 1,3-Dioxygenation of Unactivated Cyclopropanes Using a Hypervalent Iodine Reagent
作者:Matthew H. Gieuw、Zhihai Ke、Ying-Yeung Yeung
DOI:10.1002/anie.201713422
日期:2018.3.26
A facile and effective system has been developed for the regio‐ and chemoselective ring‐opening/electrophilic functionalization of cyclopropanes through C−C bond activation by [bis(trifluoroacetoxy)iodo]benzene with the aid of the Lewis basic promoter p‐toluenesulfonamide. The p‐toluenesulfonamide‐promoted system works well for a wide range of cyclopropanes, resulting in the formation of 1,3‐diol products
Electrocatalytic Activation of Donor–Acceptor Cyclopropanes and Cyclobutanes: An Alternative C(sp
<sup>3</sup>
)−C(sp
<sup>3</sup>
) Cleavage Mode
作者:Simon Kolb、Martin Petzold、Felix Brandt、Peter G. Jones、Christoph R. Jacob、Daniel B. Werz
DOI:10.1002/anie.202101477
日期:2021.7.12
We describe the first electrochemical activation of D–A cyclopropanes and D–A cyclobutanes leading after C(sp3)−C(sp3) cleavage to the formation of highly reactive radical cations. This concept is utilized to formally insert molecular oxygen after direct or DDQ-assisted anodic oxidation of the strained carbocycles, delivering β- and γ-hydroxy ketones and 1,2-dioxanes electrocatalytically. Furthermore
Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:
4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
申请人:Schnute Edward Mark
公开号:US20050004161A1
公开(公告)日:2005-01-06
The invention provides a compound of formula I:
wherein A, B, R
1
, R
2
, R
3
, and R
4
are as defined in the specification. The compounds of the present invention are useful for treating viral infections, in particular a herpesviral infection.
[EN] NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS<br/>[FR] NOUVEAUX DIESTERS PHOSPHORIQUES CYCLIQUES DE DIOLS DE 1,3-PROPANE-1-ARYLIQUES ET LEUR UTILISATION POUR LA PREPARATION DE PROMEDICAMENTS
申请人:METABASIS THERAPEUTICS INC
公开号:WO2004041834A2
公开(公告)日:2004-05-21
Compounds of Formula (I), their preparation and synthetic intermediates, and their use in the synthesis of prodrugs; wherein: V and L are trans relative to one another; V is selected from group consisting of carbocyclic aryl, substituted carbocyclic aryl, heteroaryl, and substituted heteroaryl; and L is a leaving group selected from the group consisting of halogen, alkyl sulfonate, aryloxy optionally substituted with 1-2 substituents, N-containing heteroaryl, and N-hydroxy-nitrogen containing heteroaryl; and salts thereof.